There are two strategies to treating cancer through immunotherapy: passive and active. Passive immunotherapy involves treatments with monoclonal antibodies, adoptive T cell transfers, and genetically engineered T cells, whereas active immunotherapy involves vaccine-mediated immunity via the administration of tumor-associated antigens (Banerjee et al. 2018). Due to genetic alterations or post-translational modification of proteins, cancer cells can express and display proteins that differ from their normal cell counterparts or are overexpressed in the tumor phenotype (Battaglia et al. 2016). These proteins are known as tumor-associated antigens (TAA) and fail to be recognized by the immune system. As a result, cancer cells that display TAAs are able to evade the normal destructive response of active CD8+ T cells. Cancer vaccines serve as methods of active immunotherapy that can stimulate the CD8+ T cell response to these TAAs and hopefully eradicate all cancerous cells that display them (Banerjee et al. 2018).
Comments
Suggestion
You said cancer cells overexpress the tumor phenotype. I think you mean that they express the tumor phenotype and overexpress genes that promote cell growth and division.
Suggestion
"cancer cells can express and display proteins that differ from their normal cell counterparts"
What is the difference between express and display here? If display means something different from express, I think it would be helpful to define it, because it is unclear. If display means the same thing, then it is redundant and you could remove it.